Compare PCRX & MMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCRX | MMI |
|---|---|---|
| Founded | 2006 | 1971 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | N/A | N/A |
| Metric | PCRX | MMI |
|---|---|---|
| Price | $23.05 | $25.62 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 6 | 2 |
| Target Price | ★ $35.33 | $28.00 |
| AVG Volume (30 Days) | ★ 775.3K | 282.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.99% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.21 | $18.40 |
| Revenue Next Year | $8.26 | $14.42 |
| P/E Ratio | $48.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.80 | $24.43 |
| 52 Week High | $27.64 | $39.59 |
| Indicator | PCRX | MMI |
|---|---|---|
| Relative Strength Index (RSI) | 58.70 | 45.26 |
| Support Level | $20.88 | $24.65 |
| Resistance Level | $21.60 | $26.35 |
| Average True Range (ATR) | 0.80 | 1.13 |
| MACD | 0.39 | -0.05 |
| Stochastic Oscillator | 93.52 | 40.36 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.